Achieve Life Sciences, Inc. (NASDAQ:ACHV) Q3 2022 Earnings Call Transcript

Jim Molloy: And final question for me. Thank you for that. As look at — your scientists are going to have some free time coming up here second half 2023 or at least as ORCA-3 runs out. Any thoughts to the next things to bring in, if anything else makes sense to bring in?

John Bencich: Yes. Good question. We’ve often looked at what might be complementary to what we’re working on. I think for us the most seamless expansion has been into the vaping indication and leveraging cytisinicline across — at the moment other nicotine addictions. But as you may be aware, there could be other addictions outside of nicotine that could be applicable for cytisinicline. But it’s something that we’re always kind of scanning the horizon to see if there’s other assets that may make sense that are complementary. And I think if things continue to progress successfully, it’s something that we will continue to evaluate.

Jim Molloy: Great. Thanks for taking the questions.

John Bencich: Thanks, Jim.

Operator: And at this time, I would now like to turn it back to management for any closing remarks. Thank you.

John Bencich: Thanks operator, and thanks everyone for joining us today. We’re excited about continuing to deliver on our milestones having both of our current pivotal trials now fully enrolled with ORCA-3 as well as ORCA-V1. And we look forward to the continued progress in bringing forth the trial results to everyone in the second quarter of next year. So, I appreciate everyone’s continued interest. We look forward to providing further updates in the near future.

Operator: Thank you. This does conclude today’s conference. We thank you for your participation. You may disconnect your lines at this time and have a wonderful day.